Boehringer Ingelheim GmbH
http://www.boehringer-ingelheim.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Boehringer Ingelheim GmbH
Finance Watch: Lilly, Fosun Reveal Strategic Investments In Start-Ups, Growth-Stage Firms
Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.
Pfizer’s Mixed Readout Places Doubt On Oral GLP-1 For Obesity
Twice-daily danuglipron reduced weight in a Phase IIb trial but with a poor side-effect profile and high discontinuation rates. Pfizer is working on a once-daily formulation it hopes will offer better tolerability.
Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’
Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.
Drug Candidates For NASH & Epilepsy Disorder Secure EMA PRIME Designations
The developers of survodutide and elsunersen will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abexxa Biologics Inc
- AMAL Therapeutics SA
- ICD Therapeutics
- NBE Therapeutics AG
- SSP Co., Ltd.
- Vira Therapeutics GmbH (Vira T)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice